• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca upgraded by UBS

    2/13/25 8:39:12 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email
    UBS upgraded AstraZeneca from Neutral to Buy
    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/22/25 6:33:10 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/16/25 6:49:30 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/14/25 10:30:50 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Financials

    Live finance-specific insights

    See more
    • Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

      Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. There are 1.3 billion people worldwide livin

      7/14/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

      Investment will support AstraZeneca's ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company's largest single investment in a facility to date AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in A

      7/21/25 5:35:00 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer

      Longer-term follow up in the FLAURA2 Phase III trial confirms the favorable benefit-risk profile of this combination Overall survival results reinforce TAGRISSO as the backbone therapy in EGFRm lung cancer across stages Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to TAGRISSO monotherapy for patients with 1st-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-sm

      7/21/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

      Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca's ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation granted by FDA across the oncology portfolio of Daiichi Sankyo ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi S

      7/17/25 8:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

      In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

      2/26/24 9:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/4/22 9:06:48 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/3/21 1:13:21 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care